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HEPATOLOGY Vol. 21, No. 1, 1995

Fulminant Hepatic Failure: Summary of a Workshop
JAY
H. HOOFNAGLE,l ROBERT
L. CARITHERS,JR,’ CRAIG SHAPIR0,3AND

Fulminant hepatic failure (FHF) is defined by the appearance of severe liver injury with hepatic encephalopathy in a previously healthy person. There are an estimated 2,000 cases of FHF in the United States yearly,
representing 0.1% of all deaths and, perhaps, 6%of liverrelated deaths. The causes of FHF are many, the chief
ones in the United States being hepatitis A; B; non-A,
non-B and drug induced liver disease. There are no specific therapies for FHF, however, liver transplantation
is recommended for situations in which spontaneousrecovery appears unlikely. Factors that are valuable in
assessing the likelihood of spontaneous recovery are
static features such as patient age and etiology of FHF
and dynamic features including encephalopathy grade,
prothrombin time, and serum bilirubin. Presently, approximately 7% of all liver transplants are done for FHF
and the 1-yearpatient survival rates average 63%, somewhat less than survival rates for nonfulminant liver disease, averaging 78%. The management of patients with
F” is challenging, particularly important being monitoring and early treatment of infections, hemodynamic
abnormalities, and brain edema. Innovative approaches
to management and therapy include use of cytoprotective or antiviral medications, hepatic support systems,
extracorporeal liver support, hepatocyte transplanta-
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tion, auxiliary liver transplantation, and xenotransplantation. None of these are of proven benefit, but many are
promising as a means to support the patient with FHF
until spontaneous recovery occurs or a suitable liver
graft is available for transplantation. (HEPATOLOGY
1995;21:240-252.)

Fulminant hepatic failure (FHF) is one of the more
dramatic and challenging syndromes in clinical medicine. At present, there are no universally accepted criteria for the diagnosis of FHF. For practical purposes,
FHF is defined by the appearance of severe acute liver
disease with hepatic encephalopathy in a previously
healthy person.’ Hepatic failure is often referred to as
subfulminant if onset of encephalopathy occurs more
than 8 weeks after onset of jaundice. FHF represents
a clinical syndrome rather than a specific disease and
can be caused by a variety of viruses, drugs, toxins,
and metabolic disorders.
The mortality rate of FHF is high, and there is no
effective therapy for any of its major causes. Nonetheless, medical therapy is critical in dealing with the
many complications of FHF, including bacterial and
fungal infections, hemodynamic instability, brain
edema, renal and pulmonary failure, acid-base and
electrolyte disturbances, and coagulopathy. Orthotopic
liver transplantation (OLTx) has been used increasingly as an alternative to conservative medical management in patients with FHF in whom spontaneous
survival is deemed to be unlikely. Critical in the decision to use OLTx is the assessment of the likelihood of
spontaneous recovery. OLTx commits the patient to a
life-long need for immunosuppression to prevent graft
rejection. The timing of OLTx in patients with FHF
also is critical; a donor liver is often needed rapidly, and
any delay can result in appearance of severe infectious
complications or permanent neurological damage. Finally, long-term survival after OLTx for FHF has been
relatively poor in comparison with survival after OLTx
for other conditions. These considerations make the
role of OLTx in management of FHF particularly challenging and controversial. New and better means of
management are needed.
On February 1 to 2, 1993, the National Digestive
Diseases Advisory Board sponsored a workshop entitled “Current Issues in the Management of Fulminant
Hepatic Failure” to address recommendations for the
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produces infection and disease but not hepatitis B surface antigens (HBsAg) or hepatitis B e antigens
(HBeAg). For instance, the well-described HBeAg-negHepatitis A
5 (8%)
ative mutant of HBV, which has a mutation in the
Hepatitis B
9 (15%)
precore region that blocks synthesis of HBeAg, has
Hepatitis C
0
been linked to FHF in several areas of the world.
Hepatitis non-A, B, or C
23 (38%)
Omata et a15found precore mutations in seven of seven
Acetaminophen
11 (18%)
Japanese patients with fulminant hepatitis B. SimiToxins or drugs
9 (15%)
larly, Liang et a16 found precore mutants in all five
Miscellaneous
3 (5%)
patients with FHF in an outbreak of hepatitis B in
Israel. In Western countries, the precore mutant appears to be less important as a cause of FHF.7 Furthercurrent medical management of this condition, the role more, it is not clear whether the precore mutant actuof OLTx, and the role of new and evolving innovative ally predisposes patients to more severe hepatitis or
approaches in this challenging clinical condition.
whether these reports represent peculiar outbreaks.
HBV mutants with defects in the HBsAg gene also
CAUSES OF FHF IN THE UNITED STATES
have been described and may account for some cases
The causes of FHF in the United States were dis- of cryptogenic FHF.',' A number of investigators have
cussed by Dr Teresa Wright (Department of Medicine, found HBV DNA by Southern blot analysis in livers of
Veterans Affairs Medical Center and University of Cal- HBsAg-negative patients with FHF. HBsAg was not
ifornia, San Francisco, CA [UCSFI).FHF can be caused detected in serum of these patients before OLTx, but
by viruses, drugs, toxins, and miscellaneous conditions, the patients became positive for it after transplantaincluding Wilson's disease, Budd-Chiari syndrome, tion. The role that these cryptic cases of hepatitis B
ischemia, and hyperthermia.' Identifying the cause of play in the overall prevalence of FHF deserves further
FHF in individual cases is important because of impli- evaluation.
Hepatitis E virus (HEV) infection is another potencations for prognosis, therapy, and prevention. Diagnosis requires application of intensive epidemiological, tial cause of FHF that might be missed by conventional
clinical and serological methods. The results of analysis serological testing. Hepatitis E can lead to FHF, particof a cohort of 60 cases of FHF referred to UCSF between ularly in pregnant women. The methodology for diagnosis of hepatitis E is still problematic. Among five
1989 and 1992 are shown in Table 1.
In this series and in others, hepatitis A and B were studies from Western countries, hepatitis E was identithe most frequently identified viruses causing FHF.' fied in only two studies, and it accounted for only 6 of
Although no cases were identified in this series, hepati- 97 (6%) total cases.'
Many drugs are capable of inducing FHF, and some
tis D and E account for a variable but usually small
proportion of cases of FHF in Western countries. Most cases of cryptogenic disease may be caused by exposure
striking, however, was that hepatitis C did not account to a medication or toxin in the environment that is not
for a single case, despite the use of sensitive serological considered significant or is not recognized or rememtests for hepatitis C virus (HCV) RNA as well as anti- bered by the patient. Careful toxicological screening
body to HCV (anti-HCV). This low rate of fulminant may help detect some of these cases. Less common
hepatitis C has been found by others: in a recent sum- causes of FHF include Wilson's disease, shock or ismary of four studies using tests for anti-HCV and HCV chemia, hyperthermia, hypothermia, Budd-Chiari synRNA, hepatitis C accounted for only 2% of cases of FHF drome, malignancy, and the microsteatosis syndromes
(2 of 81 patients).2Occasionally, chronic HCV infection of fatty liver of pregnancy, Reye's syndrome, and drugappeared to be a cofactor with acute hepatitis B in induced steatosis. The differential diagnosis of FHF
should lead t o careful search for causes before the term
causing FHF.3
These findings, as well as results from other investi- cryptogenic is applied.
However, despite intensive analysis and use of the
gators, indicate that the single most common etiology
of FHF is unknown. FHF can also be caused by other most modern techniques, the cause of most cases of
nonhepatotropic viruses, such as Epstein-Barr virus, FHF remains unknown. This finding calls for further
cytomegalovirus, adenoviruses, and herpes simplex vi- intensive research, using animal models as well as the
rus, but these are exceedingly rare causes of FHF and most innovative molecular techniques, to help define
usually present with distinctive clinical features. Pre- and eventually prevent or treat these unknown but
liminary findings suggesting that a paramyxovirus important causes of FHF.
may account for some cases, especially those associated
EPIDEMIOLOGY
with giant-cell formation, remain un~onfirmed.~
Thus,
The epidemiology of FHF in the United States was
most FHF in the United States is best described simply
discussed by Dr Craig Shapiro (Medical Epidemioloas cryptogenic.
Some cases of cryptogenic FHF may actually be gist, Hepatitis Branch, Centers for Disease Control and
caused by hepatitis B. Mutations in critical hepatitis Prevention [CDC], Atlanta, GA). The most comprehenB virus (HBV) genes may cause a mutant virus that sive system with data on the mortality from acute hepaEtiology
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TABLE
2. Estimated Deaths Caused by Acute Viral
Heuatitis. United States
Type

Hepatitis A
Hepatitis B
Non-A, non-B
Total

Case
Fatality

Estimated No.
of Icteric Cases

Estimated
No. of Deaths

0.2%-0.4%)
1.0%-1.2%
1.5%-2.5%

75,000
100,000
37,500
212,500

120-304
950-1,220
570-950
1,640-2,474

3. Number of Cases of OLTx for FHF
TABLE
by Year in the United States
Year

Total no. of OLTx
for FHF (%I
NO.O L T ~

1988

1989

1990

1991

1,488
110
(7.4%)

1,853
126
(6.8%)

2,307
167
(7.2%)

2,574
149
(5.8%)

There are approximately 2 million deaths per year
in the United States. Information on the major cause
titis and the incidence of hepatitis in the United States
of death and on up to 20 contributing causes is included
is the Viral Hepatitis Surveillance Program (VHSP), a
on all death certificates. There are no International
nationwide system operated by the CDC that provides Classification of Diseases-9th Revision, (ICD-9) codes
demographic, diagnostic, risk factor, and outcome inspecific for FHF. Using hepatic coma without mention
formation on reported cases of acute viral hepatitis.
of chronic liver disease, alcoholism, or neoplasm as an
Between 1983 and 1989,169,666 cases of acute hepatiassociated condition as a means of capturing cases, aptis were reported to the VHSP, of which 1,565 (.9%)
were fatal." The fatality rate was lowest for hepatitis proximately 7,489 deaths from FHF could be identified
A (328 of 80,689, 0.4%), intermediate for hepatitis B between 1980 and 1988, an incidence of 3.5 deaths
caused by FHF per million people. Rates were higher
(948 of 77,490,1.2%)and highest for non-A, non-B hepfor men than women and for blacks than whites.
atitis (289 of 11,487,2.5%).Age-specific rates indicated
Statistics from the National Hospital Discharge Surthat mortality was higher in patients 50 years of age
vey
include detailed information on discharge diagnoor older and in those younger than 5 years of age for
500 hospitals in the United States. Between
ses
from
all forms of hepatitis. Because this system relies on
1988
and
1990 there were an estimated 23,103 total
passive surveillance, reporting of cases is incomplete,
hospital
discharges
coded as hepatic coma without
and severe cases (including deaths) may be more likely
to be reported than milder cases. Therefore, the calcu- mention of chronic liver disease, alcoholism, or neoplasm. This estimate converts to a rate of 31.2 hospitallated fatality rates may be high.
izations
for FHF per million people. The average hospiMore accurate but geographically limited data on the
for this diagnosis was 17.5 days, yielding an
tal
stay
incidence and mortality of acute viral hepatitis is availestimated
135,000 hospital days per year. As with
able from the Sentinel Counties Study, an intensive
death
certificate
information, the rate of hospitalizasurveillance system for all cases of viral hepatitis in
tion
for
this
diagnosis
was higher in blacks than whites
four counties in the United States.l12l2In this system,
but
was
equal
in
men
and women.
patients with acute hepatitis are interviewed by
Obviously,
better
information
on the epidemiology
for
trained personnel, and serum samples are obtained
of
FHF
is
needed.
The
current reporting
and
incidence
special serological testing. Thus, more accurate demosystems
suggest
that
there
are
approximately
2,000
graphic characterization and diagnosis are possible.
to
viral
hepatitis
yearly,
deaths
from
FHF
related
This important study has provided key information on
the epidemiology, mode of transmission, pathogenesis, which would represent approximately 0.1% of all
and natural history of acute and chronic viral hepatitis deaths and perhaps 6% of liver-related deaths.
in the United States. Between 1982 and 1990, 11,226
CURRENT STATUS OF LIVER
cases of acute hepatitis, of which 88 were fatal (0.8%),
TRANSPLANTATION FOR FHF
were entered into the Sentinel Counties Study. The
mortality rate was 0.2% for hepatitis A (7 of 4,251
The current use of OLTx for FHF in the United
cases), 1%for hepatitis B (42 of 4,410 cases), and 1.5% States was reviewed by Dr Katherine Detre (Professor
for non-A, non-B hepatitis (39 of 2,565 cases).
of Epidemiology, Graduate School of Public Health,
The application of the case-fatality rates obtained University of Pittsburgh, Pittsburgh, PA). Information
from VHSP and the Sentinel Counties Study to the was obtained from the United Network for Organ Sharestimated annual number of cases of icteric hepatitis ing (UNOS), which collects a limited amount of inforin the United States suggests that there are approxi- mation on all transplantations performed in the United
mately 2,000 deaths from acute viral hepatitis yearly States.15 Supportive data is also available for the Na(Table 2).
tional Institute of Diabetes and Digestive and Kidney
Because FHF has causes other than acute hepatitis, Diseases (NIDDK) Liver Transplantation Database. l6
surveillance systems have limitations in making infer- According to information from UNOS, FHF accounts
ences about the incidence of FHF. Two other systems for approximately 7% of OLTx performed (Table 3).
can be used to assess mortality and morbidity of FHF:
This indication for transplantation was more fremultiple cause of death data and the National Hospital quent for children (11%to 13%)than for adults (6% to
Discharge Survey, both from the National Center for 7%). Overall, the median age of persons who received
Health Statistics (NCHS).13,14
transplants for FHF (28 years) was lower than the me-

HEPATOLOGY
Vol. 21, No. 1, 1995

HOOFNAGLE ET AL

TABLE4. Etiology of FHF in Patients Undergoing OLTx
Etiology

Not specified
Hepatitis A
Hepatitis B
Hepatitis C
Non-A, non-B hepatitis
Drug-induced injury
Other

Children
(n = 146)

Adults
(n = 424)

47.3%
10.3%
4.1%

25.9%
6.6%
23.4%
3.8%
22.6%

-

26.7%
9.6%
2.1%

16.0%

1.7%

dian age for people who received transplants for other
causes (44 years), this differential holding true even
when adults were analyzed separately. FHF was a
more frequent indication for OLTx for minority groups
than it was for whites.
The major cause of FHF leading to OLTx was unknown (‘‘not otherwise specified), followed by “non-A,
non-B” hepatitis, hepatitis B, drugs, and hepatitis A
(Table 4). Acetaminophen overdose or toxicity accounted for 2% of FHF cases in children and for 5% in
adults.
FHF patients undergoing OLTx were more likely to
be on life support than were those undergoing transplantation for nonfulminant diseases (60% vs. 10% in
adults), and the waiting time for transplantation was
considerably shorter (mean, 5.3 days vs. 60.4 days in
adults; 7.5 days vs. 106.1 days in children). Patients
with FHF received liver transplants from donors with
similar characteristics (age, cause of death, and so on),
except for children, who were more likely to receive
a liver from an older donor if they had FHF. More
importantly, however, patients with FHF were more
likely to receive an incompatible blood group system
(ABOkmatched donor (11%vs. 1.9%in adults; 17.7%
vs. 5.7% in children). Finally, patients with FHF had
lower rates of patient and graft survival than patients
with nonfulminant disease (Table 5 ) .
The relative risk for survival for 1 year for cases that
received transplants for FHF was 1.89 (95%confidence
interval [GI] = 1.66-2.15)for graft failure and 1.91 (95%
GI = 1.65-2.21) for death indicating worse prognosis
for OLTx for FHF than for other causes. However,
when risk was adjusted for multiple factors that differed between patients with FHF and those with other
causes for OLTx, the relative risk decreased to approximately 1.00 for both 1-year graft and patient survival.
The most important factor was the recipient functional
status, especially the need for life support. Age of the
patient, donor age, cause of FHF, and pretransplantation laboratory values did not appear to correlate with
poor outcome. Thus, survival after OLTx for FHF was
not different than it was for other indications when the
clinical condition of the patient was considered.
PROGNOSTIC FEATURES IN FHF

The decision to perform OLTx for a patient with FHF
must take three questions into consideration: (1) Is
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spontaneous recovery probable? (2) If not, is transplantation feasible? (3) Or, have irretrievable complications occurred?
Spontaneous recovery is certainly the preferable outcome in FHF because most patients are left with no
residual liver disease, and thus they avoid the risk and
expense of the transplantation itself and the lifelong
immunosuppressive therapy. On the other hand, recovery from FHF may not be possible, in which case urgent
OLTx is the only option. Timing is critical to successful
transplantation; if OLTx is performed too early, it may
not have been necessary; if it was performed too late,
the patient with FHF may have already developed severe neurological damage or a life-threatening infection. The critical decision of when to perform OLTx
requires knowledge of accurate and sensitive prognostic factors for determining the likelihood of spontaneous recovery.
Predictive factors for survival in FHF were outlined
by Robert L. Carithers, Jr, MD, (Department of Medicine, University of Washington, Seattle, WA). Prognostic factors for survival in FHF have been extensively
analyzed in large series of patients from Boston,I7Los
Angeles,18Paris,lg and London.20.21
From these studies,
two types of clinical variables have been identified as
helpful in assessing prognosis: static variables, which
are present at the time of admission and do not change
(such as patient age, race, gender, and cause of disease), and dynamic variables, which do change during
the course of illness (such as degree of coma, serum
bilirubin, and prothrombin time).
Static variables that have been found to correlate
with survival from FHF are patient age and etiology.
Survival rate in patients between the ages of 10 and
40 years is between 30% and 35%, whereas survival
rate in patients older than 40 years of age or younger
Patients
than 10 years of age is poor, less than 10%.17-21
with hepatitis A and acetaminophen toxicity have the
highest survival rate; those with hepatitis B and D
have intermediate survival rates; and patients with
drug-induced liver disease and with cryptogenic FHF
have the poorest survival rates.’8-20Patients with Wilson’s disease or malignancy-induced FHF rarely survive.
Dynamic variables useful in predicting the outcome
of FHF include degree of hepatic encephalopathy, prothrombin time, factor V level, serum bilirubin, serum
creatinine, alpha-fetoprotein level, arterial pH, and arterial ketone body ratio.’’ The degree of encephalopathy is a strong predictor of outcome. Among patients
who reach only stage I1 encephalopathy, the possibility
of spontaneous recovery is between 65% and 70%,with
TABLE5. 1-Year Survival Rate After OLTx
Group

Patient
Survival

Graft
Survival

All FHF cases
All non-FHF cases

63%
78%

53%
70%
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stage I11 between 40% and 50%, and with stage IV 20%
or 10wer.l~
In recent years, sophisticated multivariate analysis
and prognostic modelling have been applied to static
and dynamic variables to assess the relative importance and interaction in predicting outcome. Bernuau
et all9from the H8pital Beaujon, Clinchy, France, analyzed features from 115 consecutive patients with FHF
caused by hepatitis B. Variables found to correlate best
with survival were the factor V level ( P < .001), patient
age ( P = .001), absence of HBsAg ( P = .06), and level
of alpha-fetoprotein ( P = .07). Subsequently, Williams
et a1 from the King's College Liver Unit (London) analyzed data on 588 patients admitted with FHF to their
For
care, 310 of whom had acetaminophen toxicity.20,21
the total cohort, the static variables found to be most
important in predicting prognosis were patient age (P
< .Ol), disease etiology (P < .001), encephalopathy
grade ( P < .05), and, for nonacetaminophen cases, duration ofjaundice ( P < .001).Analysis of dynamic variables showed that admission and peak serum bilirubin
and prothrombin times were important. In patients
with acetaminophen-induced FHF, arterial pH on admission and serum creatinine were also important.
Based on their multivariate analysis, the King's College group have proposed the following criteria for
transplantation in patients with FHF.20,21For acetaminophen hepatotoxicity: Arterial pH <7.30 or the
following three factors: prothrombin time >100 seconds, creatinine >3.5 mg%, and grade I11 or IV encephalopathy. For other causes of FHF: Prothrombin time
> l o 0 seconds or any three of the following: prothrombin time >50 seconds, bilirubin >17.5 mg% (100 pmol),
age younger than 10 years or older than 40 years,
cryptogenic or drug-induced FHF, or jaundice for more
than 7 days before onset of encephalopathy.
Using both static and dynamic variables, important
information of prognosis can be gained to estimate the
probability of spontaneous recovery. These carefully
defined criteria for judging prognosis are extremely valuable but need to be continuously re-evaluated and revised based on other advances in the management of
FHF.
COMPLICATIONS OF FHF

The medical complications of FHF were discussed by
Andres Blei, MD (Department of Medicine, Lakeside
VA Medical Center and Northwestern Medical Center,
Chicago, IL), and new approaches to their management
were discussed by Gregory Gores, MD (Division of Gastroenterology, Mayo Clinic, Rochester, MN). Common
complications of FHF include infections, hemodynamic
changes, mental status changes, and brain edema.
Infections. Infections are a common complication
and significant cause of death in patients with FHF.
In a prospective study of 50 patients with FHF who
had daily bacterial cultures, investigators at the FHF
unit at King's College found evidence of infection in
90% of patient^.'^ A third of patients had fungal infections in addition to bacterial infections. Most patients

HEPATOLOGY
January 1995

had few systemic manifestations of infections such as
fever or elevated white blood cell counts. Thus, without
careful monitoring and routine cultures, many infections can be missed before death.
Spontaneous bacterial peritonitis also is common
among patients with FHF. Chu et alZ4found that 32%
of 82 patients with severe acute hepatitis and subacute
hepatic necrosis developed bacterial peritonitis. Patients with peritonitis or other infections were more
likely to develop renal failure and gastrointestinal
bleeding and had a significantly higher mortality than
did noninfected patients.
The frequency of severe infections during the course
of FHF has led to trials of preventive therapy. Prophylactic therapies have focused on control of bowel flora,
the suspected source of most bacteremias in FHF. In
a controlled trial from the King's College FHF group,
prophylactic antibiotics led to a significant decrease in
bacterial infections. Although survival was greater in
patients given prophylactic antibiotics, this did not
reach statistical ~ignificance.'~
However, the rate of
successful transplantation was greater in patients
given antibiotics, and the investigators concluded that
prophylaxis was appropriate for all patients with FHF
and stage I11 encephalopathy. In a separate study from
Barcelona, Spain, investigators found that broad-spectrum antibiotics led to a decrease in mortality rate and
shortened hospital time in patients with FHF.26Thus,
two recent controlled trials indicate that prophylactic
antibiotics are appropriate in the management of FHF.
Hemodynamic Changes. Patients with FHF can
experience marked changes in systemic and portal
hemodynamics, including acute portal hypertension,
systemic hyperdynamic circulation, and profound peripheral vasodilation. For instance, in one study, portal
hypertension was present in 24 of 25 patients with FHF
who underwent hepatic venous pressure measurem e n t ~ Raised
. ~ ~ portal pressures correlated with the
degree of architectural disruption of the liver and were
most evident in patients with ascites and renal failure.
Patients with FHF typically had a hyperdynamic circulation with a low systemic vascular resistance and
markedly increased cardiac output similar to what is
found in chronic liver disease. The cause of these circulatory changes are unclear; from studies of chronic liver
disease, a variety of mediators have been proposed,
including bile salts, prostaglandins, glucagon, endotoxin, serotonin, nitric oxide, and nonhumoral neural
substances. The circulatory changes, which can be profound, are associated with renal vasoconstriction, a decrease in cerebral perfusion pressure (CPP),and hepatopulmonary syndrome. The renal vasoconstriction
leads to a picture of renal failure similar to the hepatorenal syndrome observed in chronic liver disease. In
addition, prolonged inappropriate arteriolar vasodilatation can interfere with the normal autoregulation of
capillary oxygen consumption and predispose the patient to lactic acidosis.
In one clinical trial," prophylactic acetylcysteine or
placebo was administered to 50 patients with acet-
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aminophen-induced FHF in an attempt to decrease tissue injury by augmenting intracellular sources of cysteine and glutathione. Therapy was associated with an
increase in oxygen delivery and a decrease in lactic
acidosis although cardiac output was increased and peripheral vascular resistance was further de~reased.'~
Brain Edema. In addition to encephalopathy, FHF
is commonly associated with brain edema, which can
evolve to an increase in intracerebral pressures (ICP),
a common immediate cause of death in FHF. Increased
ICP is uncommon in patients with stage I and I1 encephalopathy but eventuates in the majority of patients
in stage IV coma. It is clear that there is an increase
in brain water before brain edema becomes clinically
apparent as increased ICP.
The cause of brain edema in FHF is not well defined;
but it is probably multifactorial. Theoretically, it could
be caused either by disruption of the blood-brain barrier with direct leakage of plasma into the cerebrospinal fluid (CSF) (vasogenic mechanism) or by cellular
alterations that allow increased uptake of water into
brain cells (cytotoxic mechanism). The majority of experimental evidence favors the latter mechanism, a
concept that is supported by clinical observations that
mannitol is effective and corticosteroids are ineffective
in reducing ICP in FHF. Three hypotheses have been
proposed to explain the cellular defect that leads to
brain edema in FHF: (1)inhibition of Na'-K' adenosine triphosphatase (ATPase) activity; (2) astrocyte
swelling; and (3) osmotic effects of accumulation of an
intracellular molecule, possibly g l ~ t a m i n e . " - ~ ~
Further studies on the cause and prevention of complications of acute liver injury are needed. Three major
areas deserve particular emphasis: (1)prevention of
infections; (2) analysis of the prognostic implications
of hemodynamic changes, renal failure, and metabolic
acidosis; and (3) understanding the pathogenesis of
brain edema. Optimal management of these complications of FHF may well lead to improvements in survival.
INTRACEREBRAL PRESSURE
MONITORING IN FHF

The major cause of death in patients with FHF
awaiting liver transplantation is brain edema. Furthermore, brain edema is found on autopsy in 80% of patients dying of FHF. Dr John Lake (Department of
Medicine, University of California, San Francisco, CA)
summarized recent findings using ICP monitoring,
which has been increasingly used in patients with FHF
to allow for proper management of brain edema and to
aid in the decision to perform OLTx.
ICP monitoring had its foundation in the management of Reye's syndrome in the 1960s and 1 9 7 0
These studies indicated that if cerebral perfusion pressure (CPP = mean arterial pressure - ICP) remained
<40 mm Hg, death or severe neurological complications were all but certain. Concerns over complications
of inserting ICP monitors led to attempts to develop
clinical findings indicative of a low CPP. Sluggish pu-
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pillary reflexes, hyperventilation, and increased systemic blood pressure occur early with increasing ICP.
Myoclonus, increased muscle tone, decorticate posturing, and seizures occur late. In studies of ICP at King's
College, clinical manifestations commonly occurred
with ICP of greater than 30 mm Hg, but there was a
poor correlation between the height of the ICP and
specific clinical signs.33334
Computed tomography (CT)
scan of the brain has likewise been found to be unreliable in detecting early brain edema. Furthermore, transport of the patient to the radiology department for CT
scan can precipitate increases in ICP and neurological
damage.
Slightly more than half of transplantation programs
in the United States routinely use ICP monitoring in
management of cases of FHF. Three types of monitors
have been used: epidural, subdural, and parenchymal.
The epidural monitor is outside the dura and, therefore, is less invasive and has fewer complications. However, it is also somewhat less reliable than the subdural
or parenchymal monitors. ICP monitoring has compli~~
cations. A recent review of ICP r n o n i t ~ r i n gindicated
that the complication rates were 4% (6 of 160) for epidural, 20% (16 of 79) for subdural, and 22% (5 of 23)
for parenchymal monitors. Deaths from infection or
bleeding were reported with all three types of monitoring but were less common with the epidural (-1%)
than with others (4% to 5%).
In many transplantation centers, epidural monitoring has become a standard practice for patients with
FHF.36The monitor is placed at the onset of stage IV
coma or if there is rapid progression into stage I11 coma.
A brain CT scan is performed before placement, and
any coagulopathy is corrected with fresh frozen plasma
(to keep prothrombin time <5 seconds prolonged). The
epidural ICP monitor is checked daily by neurosurgical
consultants. A repeat CT scan is performed at removal
of the ICP monitor.
ICP monitoring is valuable in guiding treatment, the
goals of which are to maintain an ICP of <20 mm Hg
and a CPP of >50 mm Hg. A standardized approach
to therapy has been adopted by the collaborating centers of the NIDDK Liver Transplantation
If the ICP rises above 20 mm Hg, (1)patients are hyperventilated to keep the P C Oless
~ than 25 mm Hg. If
there is no response or a relapse, (2) mannitol is administered (0.5 to 1gkg) as a bolus intravenously and then
as needed to keep serum osmolarity between 310 and
320 mOsm. If there is no response or a relapse with
mannitol, (3) pentobarbital coma is induced using a
bolus of 3 to 5 mgkg intravenously. Although the response rate to therapy was high, relapses were common
(Table 6).
~ ~ICP
~ monitoring not only allows for rapid and appropriate therapy of brain edema but also for avoidance
of manipulations that worsen ICP, such as excessive
physical stimulation, suctioning of the airway, or
changes in body position. ICP monitoring also has been
helpful during the transplantation procedure t o determine which anesthetic agents affect ICP the least.
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TABLE6. Outcome of ICP Monitoring in Patients With FHF

Treatment

No. of Episodes

% of Response

Initial Pressure (Mean)

Change Pressure (Mean)

% of Relapse

Hyperventilation
Mannitol
Barbiturate coma

18
11
15

82%
72%
73%

18 mm
26 mm
26 mm

3.5 mm
4.6 mm
4.6 mm

7 1%
75%
80%

From these studies, narcotics and barbiturates have
been preferred t o inhalation gases for anesthesia induction, and P-blockers have been preferred to nitroprusside for blood pressure control.
The value of ICP monitoring in selecting patients for
OLTx has recently been documented in studies at the
University of Nebraska, Omaha, NE.38When ICP monitoring was introduced, the results were not used to
decide which patients should or should not undergo
OLTx. During this early period, seven patients with a
CPP < 40 mm for more than 2 hours received transplants; all seven suffered brain death. Conversely, all
patients whose CPPs remained >50 mm recovered
without neurological sequelae. Subsequently, no patients with low CPP for more than 2 hours received
transplants, and none of those who underwent transplantation developed severe neurological sequelae.
Thus, ICP monitoring can be accomplished safely, is
more reliable than CT scans, electroencephalograms,
or neurological examination, and has excellent sensitivity and specificity in predicting brain injury. Monitoring can guide therapy of brain edema, avoiding
harmful manipulations as well as titrating therapeutic
decisions. ICP monitoring provides reliable criteria for
avoidance of OLTx in patients with irreversible brain
damage and provides evidence of impending brain
death.

at If months, and ( 3 ) progressive cerebral edema after
primary nonfunction at 3 days after OLTx. Graft failures were frequent, perhaps because of the use of ABOincompatible livers. The 7 graft failures leading to retransplantation were caused by vascular rejection (2
patients), acute rejection (2 patients), chronic rejection
(1patient), and acute hepatitis B (2 patients). Neurological sequelae were mild and limited to only 2 patients. Other chronic complications included (1)a patient with fulminant cryptogenic hepatitis who
developed chronic hepatitis B with compensated cirrhosis 2; years after transplantation; (2) a patient with
fulminant hepatitis A who developed chronic hepatitis
C but who has normal liver function tests 2 years after
transplantation; and (3) 2 patients with fulminant hepatitis B who have developed cirrhosis with normal enzymes at 3 years after transplantation.
Survival results in patients with FHF who underwent transplantation at UCSF have been comparable
with those of patients with nonfulminant diseases.
These data show that excellent results can be achieved
with OLTx for FHF when strict criteria are used for
selection and when patients' conditions are managed
with an organized and aggressive approach.
AUXILIARY LIVER TRANSPLANTATION

OLTx for FHF requires that the damaged liver be
removed and that the patient be committed to a lifeOLTx FOR F H F UCSF EXPERIENCE
time of immunosuppression. The possibility of recovery
The experience in managing patients with FHF us- from FHF makes attractive the option of auxiliary liver
ing OLTx at the UCSF was reported by Dr Nancy transplantation, in which the native liver is left in
Ascher (Department of Surgery, UCSF 1. Results using place. Dr Bruce Jarrell (Chairman of Surgery, Univeran organized medical-surgical-transplantation ap- sity of Arizona Health Science Center, Tucson, AZ)proproach have been excellent.37The approach focuses on vided an overview of auxiliary liver transplantation for
prompt diagnosis, prospective monitoring of ICP, ag- FHF.
gressive treatment of complications, and early listing
The advantages of auxiliary transplantation in FHF
for liver transplantation. If patients have prolonged are the temporary requirement for immunosuppression
periods of compromised intracranial perfusion, they drugs until the host liver recovers and the relative ease
are removed from the transplantation list.
of surgery. Two types of auxiliary liver support are
Between 1988 and 1992,60 patients with FHF were possible: heterotopic and orthotopic.
evaluated for possible OLTx for FHF. Among 24 who
In auxiliary heterotopic transplantation, the liver
presented with stage I1 to I11 encephalopathy, 11 re- graft is placed in the right upper quadrant beside the
ceived transplants (2 others died, and 11 recovered native liver. In orthotopic auxiliary transplantation, a
spontaneously). Among 36 patients presenting in stage portion of the native liver is removed and replaced with
IV coma, 17 received transplants (16 others died, and a reduced-size graft. Auxiliary heterotopic transplanta3 recovered without OLTx). Donor livers were obtained tion is technically easier than orthotopic transplantaquickly, 15 within 1 day of listing and 13 more within tion but suffers from competition between the graft and
1to 3 days. The l-year patient survival rate was 92%, native liver for portal blood supply, the tenuous nature
and the graft survival rate was 83%. The 3 deaths were of the blood supply to the graft, problems of venous
caused by (1)aspiration pneumonia and cytomegalovi- congestion, and potential lack of space. In recent years,
rus infection at 5 months, (2) aspergillus brain abscess there have been seven reports of heterotopic trans-
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plants for FHF. Three patients died shortly after transplantation; four are living, and three have had recovery
of the native liver and have stopped immunosuppression. Recovery of the native livers occurred at 5 months,
6 months, and 22 months, respectively.39340
The major difficulties with auxiliary orthotopic
transplantation relate to the technical difficulties involved in resection of the left lateral segment of the
native liver and placement of the graft (frequently a
reduced-size graft) at that site.41This operation is particularly difficult in unstable patients with FHF and
severe coagulopathy. However, the auxiliary orthotopic
transplant has a more secure portal blood supply than
the heterotopic transplant. Among seven patients from
Hanover, Germany, and Nebraska that have been reTwo
ported, three s ~ r v i v e d . ~
' deaths were caused by
development of aplastic anemia in patients with fulminant cryptogenic hepatitis.
In summary, auxiliary liver transplantation has
been used successfully in 7 of 12 patients (60%) with
FHF. Several technical problems with auxiliary transplantation need further evaluation. The advantages of
not taking immunosuppressive drugs chronically may
prove important once the overall survival of this technique has sufficiently improved.
ARTIFICIAL HEPATIC SUPPORT SYSTEMS
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hepatocytes. Of course, the ideal hepatocyte for these
devices has not been identified. Normal human hepatocytes are not readily available, grow slowly in primary
cell culture, rarely survive for more than a few weeks,
and usually rapidly lose their differentiated state and
metabolic functions. Alternatives to primary human
hepatocytes have been primary hepatocytes from other
mammalian species (pig, rat, and dog) and immortalized human liver cell lines.
Sussman et a145have investigated a human hepatoblastoma cell line (C3A cells) that shows many characteristics of differentiated mature hepatocytes, including contact inhibition, detoxification of ammonia
to urea and glutamine, metabolism of amino acids, gluconeogenesis, and integrity of the P450 system. They
have reported the development of a hepatocyte-assist
device using C3A cells grown in the extracapillary
space of a hollow-fiber dialyzer. The device has the metabolic capacity of approximately 200 g of normal liver.
In preliminary studies in a dog model of FHF with
100% mortality, the assist device led to recovery of
consciousness, decreases in alanine aminotransferase(ALT) levels, and survival in four of five animals.
Preliminary attempts to use the C3A-based hepatocyte-assist device in humans with severe liver failure
also were reported.46The system used is similar to hemodialysis: venous blood is pumped through hollow fibers and returned to the patient at a flow rate of approximately 150 mumin. A second flow path is
maintained by the continuous ultrafiltration of plasma
into the extracapillary space at a rate of 20 mllmin.
The metabolic effects of the cartridge appear to be independent of ultrafiltration; delivering the ultrafiltrate
back to the blood stream allows efficient delivery of
high-molecular weight products such as clotting factors.
To date, six patients have been treated with the hepatic-assist device. Improvements in serum ALT levels,
prothrombin time, galactose-elimination capacity, and
clinical status were noted in five patients during use
for 1to 6 days on a continuous basis. Only one patient
survived, a 12-year-old girl with syncytial giant-cell
hepatitis who recovered without OLTx after 58 hours
on the assist device and who is alive and well 1 year
later. A second patient appeared to recover from FHF
but succumbed to sepsis several days later. The remaining patients died without OLTx.
Other hepatic-assist devices are being evaluated. Demetriou et a147have recently reported successful treatment of FHF in dogs with a hepatic-assist device using
primary pig hepatocytes. This experience is now being
applied to humans with FHF.4s Thus, new refinements
in cell-based hepatic-assist devices have provided new
hope for this approach to medical therapy of FHF.

In recent years, there has been an increased interest
in the use of hepatic support systems in patients with
FHF to provide a bridge until the native liver recovers
function spontaneously or until an appropriate donor
liver is available. Breakthroughs in basic and applied
research have provided innovative approaches to the
~ ~of, ~
a cell~
possibility of artificial hepatic s ~ p p o r t .Use
based therapy for extracorporeal hepatic support was
discussed by Dr Norman Sussman (Assistant Professor, Department of Medicine and Pathology, Baylor
College of Medicine, Houston, TX).
Initial attempts at developing an artificial hepatic
support were focused on various forms of dialysis or
hemoperfusion using cartridges and membranes that
would remove low -molecular weight
Charcoal
hemoperfusion enjoyed considerable attention in the
late 1970s and early 1980s, but subsequent careful
evaluations failed to show evidence of benefit of the
procedure^,^^^^^ suggesting that something more than
removal of toxins was required to prolong life in hepatic-failure patients. These considerations led to investigation of extracorporeal-assist devices that might
provide both detoxifying and synthetic hepatic functions. The major focus of interest has been the use of
cell-based extracorporeal devices.
Several types and sources of hepatocytes have been
investigated for use in extracorporeal-assist devices.
The ideal hepatocyte would be (1)human in origin, (2)
HEPATOCYTE TRANSPLANTATION
of normal (nonmalignant) phenotype, (3) readily availAchilles
A. Demetriou, MD, PhD (Director of Liver
able, (4)rapidly and easily grown in cell culture to high
density, ( 5 ) stable and remaining in a well-differenti- Support Unit, Cedars Sinai Medical Center, Los
ated state for days or weeks, and (6) capable of the full Angeles, CA), discussed the use of hepatocyte transrange of synthetic and detoxifying features of mature plantation for management of FHF. This innovative
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alternative approach uses transplantation of hepatocytes rather than of the whole organ. This approach
would have the advantages of avoiding both major surgery and the use of a whole liver; it is technically simple
and allows the use of one or more living-related donors
and multiple courses of treatment. This technique also
might providve temporary hepatic support without committing the patient to lifelong immunosuppression. Hepatocyte transplantation has not been used in humans
with liver disease but has been applied with partial
success in several animal models of liver diseases.
The feasibility of hepatocyte transplantation has
been documented in studies of genetically deficient animals. Transplantation of normal rat hepatocytes by intraportal infusion into analbuminic rats was followed
by increasing levels of serum albumin 14 to 28 days
later, which persisted for several months.49Similarly,
in jaundiced Gunn rats with genetic deficiency of glucuronyl transferase (an animal model of CrigglerNajjar syndrome), transplantation of hepatocytes from
normal rats resulted in decreases in serum bilirubin
levels and appearance of conjugated bilirubin in the
bile.50 These studies have documented the long-term
viability of transplanted hepatocytes and identified
problems in optimizing the technique. For example, the
number and percentage of cells surviving can be increased by using hepatocytes attached to beads coated
with a collagen matrix.51 However, these cells remain
immunogenic, and if allogeneic hepatocytes are used,
a lasting problem will be the need for immunosuppression. Rejection can be partially circumvented by microencapsulation of h e p a t o ~ y t e sunfortunately,
~~;
the microcapsules usually induce an intense inflammatory
reaction that results in poor hepatocyte function. The
site of infusion of hepatocytes also is important in
achieving efficient function. Intraportal, intrasplenic,
and intraperitoneal infusions all have relative
strengths and shortcomings. For instance, infusion of
large numbers of hepatocytes into the portal vein can
induce portal hypertension.
Hepatocyte transplantation for transfer of genes to
individuals with genetic diseases has advanced from
animal experimentation to pilot trials in humans. This
approach was developed in the hypercholesterolemic
Watanabe rabbit, which has a genetic defect in the lowdensity lipoprotein (LDL) receptor similar to that of
humans with familial hyper~holesterolemia.~~
Hepatocytes were obtained from the animals by partial hepatic
resection, grown in cell culture, and then transfected
with the normal rabbit LDL receptor gene using a retrovirus vector. After reinfusion into the portal vein, the
viability of the hepatocytes was shown functionally by
decrease in serum cholesterol and histologically by
identification of transfected hepatocytes expressing
normal LDL receptor messenger RNA (mRNA). Approximately 2% of normal functional hepatocyte mass
was provided by the transplanted hepatocytes, and
these cells continued to function for several months.
These innovative studies have led to pilot trials of au-
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tologous hepatocyte transplantation in humans with
homologous type I1 hyper~holesterolemia.~~
There have been few studies on hepatocyte transplantation for FHF. Using an animal model of liver
insufficiency, Demetriou et a1 have evaluated the ability of transplanted hepatocytes to provide liver supRats underwent 90% hepatectomy, which led to
death in 24 ? 8 hours after surgery in controls. Animals
treated with infusions of either allogeneic or syngeneic
hepatocytes before hepatectomy survived for 28 ? 8
hours. Infusions of hepatocytes at the time of hepatectomy also did not prolong survival. One limitation in
using hepatocyte transplantation for treating FHF is
the need for a period of 1to 3 days for cell engraftment
before function. In addition, the altered milieu of FHF
may not provide a suitable environment for transplanted hepatocytes: the same toxin that harmed the
native liver may harm the infused liver cells, and the
usual hepatic architecture and balance of growth factors, cytokines, and nutrients necessary for hepatocyte
growth and regeneration may be lacking in FHF. Thus,
hepatocyte transplantation is a promising approach to
hepatic support in FHF but has yet to be developed
sufficiently to attempt its use in patients. Because of
limitations in the numbers of hepatocytes that can be
transplanted successfully, this technique may be more
applicable to other situations, such as correction of inherited metabolic defects.
PROSTAGLANDIN THERAPY FOR FHJ?

Specific therapies for FHF are not currently available. Antiviral therapies have shown little evidence of
benefit.56-58On the other hand, therapies directed at
limiting cell damage, providing cytoprotection, and
stimulating regeneration might have a role in management of FHF. Among cytoprotective agents, the prostaglandins have been most actively investigated.
Dr Gary A. Levy (Director, Division of Gastroenterology, Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada) provided an overview
on prostaglandins and their potential role as therapy
of FHF. The prostaglandins are a group of polyunsaturated fatty acids with major, diverse metabolic actions
on cells.59Prostaglandins are made in all cells, the liver
being particularly rich in the prostaglandin E (PGE)
series. When administered systemically, PGE has multiple effects on smooth muscle tissue, inducing widespread vasodilation, increased blood flow, hypotension,
increased cardiac output, bronchodilation, intestinal
hypermotility, and uterine contractions. Exogenously
administered prostaglandins can protect the liver
against several forms of cell injury, including hypoxic,
drug-induced, viral, and immune injury.60,61The availability of PGEl and PGE, for human use has provided
an impetus to evaluate these agents in several liver
diseases, including FHF.
Sinclair et a162 from Toronto, Canada, evaluated
PGEl in 17 patients with FHF in an open label-pilot
study. PGE, was administered by continuous intravenous infusion at a rate of up to 0.6 pg/kg/hr for as
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long as 28 days. Infusions of PGE, were generally well
tolerated. Several patients had prompt improvements
in aminotransferases. Most impressively, 12 patients
survived without transplantation, a rate (70%) far in
excess of that in most series on FHF. Unfortunately, a
subsequent uncontrolled study of FHF from France63
failed to confirm the benefit of prostaglandin therapy.
Based on their initial beneficial results, Levy et a164
began a prospective, randomized, double-blind controlled study of PGEl therapy in cases of viral- and
drug-induced FHF. Forty-one patients with FHF were
admitted to this trial; 20 received PGE1, and 21 received placebo by continuous intravenous infusions for
up t o 7 days. Overall survival was similar with both
treatments: 40% of PGEl and 38%of placebo recipients
survived. Analysis of subgroups suggested that there
might be some benefit of PGEl therapy in patients with
drug-induced FHF and viral hepatitis early in its
course. However, diarrhea, fever, and mild hypotension
occurred in patients receiving PGEl therapy. In view
of these findings, routine use of prostaglandins for FHF
outside of controlled trials must be discouraged.
EXTRACORPOREAL LIVER SUPPORT

TABLE7. Median Survival Time After Hamster-to-Rat
Xenotransplantation
Immunosuppressive
Regimen

Heart Survival
(d)

None
FK506 alone
FK506 + cyclophosphamide
FK506 + brequinar

3
4
>90
>90

Liver Survival
(d)

7
35

>90
>90

Center; transient improvements in neurological status,
ICP, and hepatic function occurred in all four patients.
One patient received an OLTx after four perfusions and
is well; the other three died of sepsis, cerebral edema,
and multisystem failure, r e ~ p e c t i v e l y . ~ ~
Thus, the conditions of four of eight patients in the
modern era have been managed successfully with ECL
support, bridging the period of FHF until OLTx could
be performed. Deaths that occurred in three patients
were unrelated to the ECL technique. Thus, ECL support offers a n attractive means of temporary support
for patients with severe FHF. Improvements in handling ECL, monitoring its efficacy, and handling problems of species incompatibility are needed before this
technique can be more broadly applied.

Dr Byers Shaw (Chairman, Liver Transplantation
Program, University of Nebraska, Medical School,
Omaha, NE) summarized recent experience using an
XENOTRANSPLANTATION
extracorporeal liver (ECL) support system in the management of FHF. In this technique, the patient's circuDr John Fung (Chief, Division of Transplantation
lation is connected to a liver outside of the body. The Surgery, University of Pittsburgh, Pittsburgh, PA) proorgan used for cross circulation may be human or from vided an update and overview on xenotransplantation
another species. The procedure was introduced by Otto and its potential role in management of FHF. The conin the late 1950s and then used sporadically. During cept of using a xenograft for transplantation is not new.
the 1970s, 40 patients with more than 90 episodes of Before 1992, 33 human xenotransplantations were reFHF were treated; 3 donors were human, 67 were pri- ported, most before the availability of cyclosporin A and
mates, 23 were pigs, and 2 were calves; acute survival FK506. The longest survival was 9 months, reported
was 35%.65
in a patient given a chimpanzee kidney.68 The most
The University of Nebraska has recently applied this successful previous experience with baboon xenotranstechnique using unwanted human donor livers in three plantation was in a neonate with hypoplastic left-heart
patients with FHF.65The patients were a 16-year-old syndrome who received a baboon heart and survived
and a 38-year-old with FHF of unknown cause and a 20 days, dying eventually of humoral-mediated rejec6-year-old with Stevens Johnson syndrome. The first t i ~ n . ~Thus,
'
xenotransplantation was unsuccessful
patient underwent ECL support for 3 days with rapid largely because of problems with humoral and cell-meimprovements in serum bilirubin and ammonia levels diated rejection.
and decreases in ICP. The second patient underwent
The development of FK506 has allowed for a reastreatment for 24 hours using a liver with marked fatty sessment of xenotransplantation. In animal studies,
infiltration; there was minimal improvement in biliru- FK506 by itself does not prolong survival of hamster
bin and ammonia levels. The first two patients subse- heart xenografts in rats; however, the combination of
quently underwent transplantation successfully. The FK506 with antiproliferative drugs, such as with
third patient underwent perfusion for 3; days with de- RS61443, brequinar, or cyclophosphamide, does.7" In
crease in bilirubin and ammonia but progressive fail- liver xenografts, combinations of FK506 with antiproliferative agents led to indefinite survival of grafts (Taure of other organ systems and death.
Five cases of ECL support using livers of other spe- ble 7). The antiproliferative agents seem to act by
cies have been reported recently from other institu- blocking formation of cytotoxic antibodies and eventutions. At Johns Hopkins University Medical Center, a ally can be discontinued, whereas FK506 blocks develporcine liver was used for 4 hours in a 20-year-old pa- opment of cellular rejection, and continuous therapy is
tient with FHF caused by hepatitis B: consciousness needed.
These experiments prepared the way for attempts at
improved, and the patient underwent successful OLTx
8 hours later.66 Four patients were treated with ECL xenotransplantation in humans. The general protocol
support using porcine liver at Duke University Medical of therapy used depletion of any natural antibody
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using plasmapheresis and affinity absorption, disruption of the inflammatory cascade with corticosteroids,
blockage of antibody production by cyclophosphamide
and/or breauinar, and inhibition of cellular rejection
with FK506 and corticosteroids.
Recently two types of xenograft donors have been
evaluated: pigs and baboons. Porcine xenotransplantation was used by investigators from Cedars sinai H~~.
pita1 in ~ 0h sg e l e s in an attempt to support a critically
ill patient with FHF until an appropriate human donor
liver was available.7i After plasmapheresis against a
porcine kidney to reduce antiporcine antibodies, the
patient underwent xenotransplantation under therapy
with cyclosporin A, azathioprine, cyclophosphamide,
and corticosteroids. Initial hepatic xenograft function
was good, but after 25 hours the graft began to fail, ICP
rose, and she died a few hours later. Autopsy showed
widespread hepatic necrosis with plugging and thrombosis of arterioles and presence of immunoglobulin G
(IgG) on endothelial cells throughout the liver. Similar
pathology was noted in porcine livers used in crosscirculation studies in patients with FHF.72Thus, problems of immediate rejection and incompatibility limit
the usefulness of porcine livers in xenotransplantation
as well as extracorporeal liver support for FHF.
In 19927 two Patients with end-stage chronic hepatitis B received orthotopic baboon liver xenografts at the
University of Pittsburgh Medical Center.73The rationale for xenotransplantation in these patients was that
the baboon is not susceptible to hepatitis B and therefore reinfection could be avoided.74The patients and
baboons were carefully matched for blood type and absence of pre-existing IgG xenoantibodies. Immunosuppressive therapy included FK506, cycbhosPhamide7
and corticosteroids. Initial graft function was good. The
baboon livers were small in comparison with those of
humans (450 to 550 g Vs- 1,200 to 1,500 g) but grew
rapidly to a size appropriate to the recipient. In both
cases, baboon Proteins (albumin, transferrin, c3)were
detected in serum, but functions seemed normal (coagulation and complement cascade). Unfortunately, both
Patients developed Persistent, Poorly explained jaundice, multiple infections, and multisystem failure. Patient no. 1died after 74 days with invasive aspergillosis; patient no. 2 died after 26 days with septicemia.
Thus, the results of xenotransplantation to date are
promising but far from satisfactory. Baboon liver xenotransplantation for FHF has not been reported but may
also be appropriate in view of the increasing problem
of human donor liver availability and the possibility of
using the baboon liver to sustain the critically ill patient with FHF until an appropriate human liver is
available. The problems that blocked success in the
past, immediate vascular rejection and severe cellular
rejection, seem to be manageable with appropriate immunosuppression, at least with baboon livers. What
remains are problems of a technical and metabolic nature. Furthermore, the shortage of baboons, ethical
considerations in using primates, and issues of trans-
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mission of infections remain as very significant issue~.~~
SUMlvLARY AND RECOMMENDATIONS

OLTx should be considered standard management
for Patients with FHF who are in stage 111to IVhepatic

encephalopathy and who fulfill criteria that indicate
that survival with medical therapy alone is unlikel~
and that irreversible neurological damage has not OCcurred. Long-term survival in such patients with FHF
is similar to that of patients with chronic end-stage
liver disease, if adverse donor (ABO incompatibility)
and recipient factors (need for ventilatory support) are
controlled for in the analysis. Strict criteria for patient
selection and timing of OLTx are of great importance in
the outcome of transplantation: the decision to perform
OLTx in FHF should be based on careful assessment
of both static and dynamic factors. Static factors of
importance are
of FHF and patient age. Dynamic
factors of importance are stage of encephalopathy, prothrombin time (or factor V levels), serum bilirubin, creatinine, arterial pH, and alpha-fetoprotein levels. Medical models for predicting survival are of great help in
reaching a decision for OLTx. Exclusion criteria are
also important: overwhelming infections and sustained
impairment in cerebral perfusion are contraindications
for OLT, which makes careful
for infections
and intracerebral pressure essential. At the present
time, use of innovative approaches to managing FHF,
such as auxiliary transplants, living related donors,
xenografts,extracorporeal human liver, and artificial
hepatic support devices, are extremely promising but
must be considered experimental.
Several recommendations can be made to improve
the general management ofpatients with FHF. In medical practice, important goals are (1)encouragement of
early referral of patients with FHF to transplantation
centers, and (2) increased use of HAV and HBV vaccine.
In public policy, important steps are (1)creation of a
new UNOS category for patients with acute FHF, (2)
increased public programs to promote awareness about
organ donation, (3) change in reimbursement practices
for OLTx for patients with FHF by Medicare and Medicaid, and (4)more aggressive labeling guidelines for
hepatotoxic drugs. In clinical research, important areas
are (1)prospective studies on the epidemiology of FHF,
(2) development of clear diagnostic criteria and better
coding systems for this diagnosis, and (3) careful design
and performance of clinical trials of new and innovative
approaches to management and treatment of FHF. In
basic research, important studies are (1) in u&-o and
in uiuo analyses of the causes of brain edema in FHF,
(2) analyses of the role of cytokines and hepatotrophic
growth factors in liver cell injury and FHF, (3) basic
virological and cell biological investigations into the
etiology of cryptogenic FHF (non-A, non-B, and non-C
hepatitis), and (4)development of animal models of
severe hepatic injury to aid in the study of pathogenesis
as well as therapy and management of FHF.
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